Global Expansion Potential for cross-border selling to include BioMatrix DES and BioFreedom Ultra in new markets where regulatory approvals are already in place or in process, leveraging Biosensors' recent Japanese PMDA and US FDA clearances to target hospitals and interventional cardiology centers.

Structural Heart Tie‑In Strategic upsell opportunities by pairing Biosensors' interventional cardiology devices with the newly acquired Allegra transfemoral TAVI system from NVT, offering bundled cardiovascular and structural heart solutions to large hospital systems seeking integrated CV care.

Clinical Evidence Push Leverage existing LEADERS FREE trial success and expanding RISE CHINA and BIO-RISE studies to drive demand for BioFreedom Ultra and BA9-based BioMatrix platforms in high-bleeding-risk and complex lesion populations.

Regional Growth Explore growth in Asia-Pacific and China where ongoing studies and PMDA approvals create momentum; align with JW Medical Systems and local distributors to accelerate adoption of BioFreedom Ultra and BioMatrix Alpha in key tertiary centers.

Strategic Partnerships Opportunity to collaborate with larger medical device players for co‑marketing, distribution, or device integration initiatives given Biosensors’ mid-market revenue size and strategic acquisitions, potentially expanding sales reach without heavy capex.